S& P 500 hits all time highs U.S.-Japan trade deal optimism
REHOVOT, Israel and SAN ANTONIO, TX - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a market capitalization of $377 million and strong financial health according to InvestingPro metrics, has announced the opening of a new plasma collection facility in San Antonio, Texas, as part of its expansion strategy. The center, operated by Kamada’s subsidiary Kamada Plasma, spans 11,100 square feet and is designed to support close to 50 donor beds, with a projected annual collection capacity of about 50,000 liters.
The facility will gather both normal source plasma and specialty plasma, including Anti-Rabies and Anti-D variants. The specialty plasma is expected to meet the growing demand for hyper-immune plasma products and may reduce the company’s raw material costs. This expansion aligns with Kamada’s impressive 12.93% revenue growth over the last twelve months and healthy 43.47% gross profit margin. Additionally, the normal source plasma collected will be sold to third parties, with expected annual revenue from these sales estimated to reach $8 million to $10 million at full operational capacity.
CEO of Kamada, Amir London, expressed confidence in the skilled team leading the new center and highlighted the strategic importance of the expansion in supporting the company’s increasing demand for specialty plasma.
Kamada plans to submit approval applications for the new site to the U.S. FDA and the European Medicines Agency in the second half of 2025, with approval decisions expected within 9-12 months of the submissions.
This development aligns with Kamada’s growth pillars, which include organic growth through commercial activities, securing new business development opportunities, expanding plasma collection operations, and advancing the development of additional product candidates.
Kamada’s portfolio includes six FDA-approved specialty plasma-derived products and other therapies for rare and serious conditions. FIMI Opportunity Funds, Israel’s leading private equity firm, is the controlling shareholder of Kamada, owning approximately 38% of the outstanding shares.
This news is based on a press release statement and reflects the company’s current plans and expectations regarding its new plasma collection center.
In other recent news, Kamada Ltd. reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.07, compared to the forecasted $0.05. However, the company’s revenue for the quarter was $39.01 million, slightly below the anticipated $40.11 million. Kamada also declared a special cash dividend of $0.20 per share, reflecting strong financial results and a solid cash position. The company forecasts significant growth in 2025, with a revenue target of $178-182 million, supported by strategic initiatives like the expansion of its biosimilar portfolio and plasma collection centers.
In related developments, Kamada announced the opening of a new plasma collection facility in San Antonio, Texas, as part of its strategy to enhance plasma collection capabilities. This move aligns with the company’s efforts to secure a stable supply of plasma, crucial for its plasma-based products. Meanwhile, H.C. Wainwright maintained its Buy rating on Kamada, with an $11 price target, citing the company’s strong performance and potential for growth in its therapeutic pipeline. The firm’s analyst, Andrew S. Fein, highlighted Kamada’s unique position as both a plasma business and a biotechnology firm, which offers a blend of stable revenue and growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.